At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 119 enrolled
Drug / intervention
branebrutinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Branebrutinib Treatment in Subjects With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Subjects With Active Rheumatoid Arthritis
In Brief
A Phase 2 clinical trial evaluating branebrutinib, abatacept, and 1 other intervention for Autoimmune Disorder and 3 related conditions. Completed, enrolled 119 participants across 81 sites in 10 countries.
Detailed Summary
The purpose of this study is to evaluate the safety and effectiveness of treatment with branebrutinib treatment in participants with active systemic Lupus Erythematosus (SLE) or Primary Sjögren's Syndrome (pSS), or branebrutinib treatment followed by open-label abatacept treatment in study participants with active Rheumatoid Arthritis (RA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAutoimmune Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Primary Sjögren's Syndrome
CountriesArgentina, Belgium, France, Germany, Mexico, Netherlands, Poland, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedDec 2019
Enrollment StartJan 2020
Primary CompletionDec 2022
TodayJul 2026
First PostedDec 5, 2019
Enrollment StartJan 7, 2020
Primary CompletionDec 5, 2022
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 6.6 years ago
Interventions
branebrutinibdrug
Specified dose on specified days
abataceptdrug
Specified dose on specified days
branebrutinib placebodrug
Specified dose on specified days